1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Brookfield announced a non-binding framework agreement between the U.S. Government and South Korea to support up to $120 billion of Korean investment in eight large nuclear reactors in the U.S. Brookfield is a shareholder in Westinghouse alongside Cameco, and the framework includes a planned Korean equity investment of 5% to 10% in Westinghouse, but the filing does not quantify Brookfield's own financial effect.
Up to $120 billion of Korean investment to help finance eight large U.S. reactors
Six Westinghouse AP1000 reactors across three two-unit plants, plus two APR1400 reactors, on U.S. federal sites
Korea would make a cornerstone equity investment of between 5% and 10% in Westinghouse
Terms are non-binding and subject to final negotiations
Sanara MedTech shareholders approved the merger agreement with MiMedx Group at a special meeting on September 30, 2026, with 6,372,989 votes for and 1,944 against. Shareholders also approved, on an advisory basis, merger-related compensation for Sanara's named executive officers. The merger still depends on the expiration of the HSR Act waiting period and the satisfaction or waiver of other closing conditions.
OpenText said it will buy up to $300,000,000 of its 3.875% Senior Notes due 2028 in a cash tender offer, but holders tendered $697,563,000, so purchases are prorated at 43.047752%. The company expects a concurrent senior secured notes offering to close on October 1, 2026, with proceeds and cash on hand used to redeem its 6.900% Senior Secured Notes due 2027 and to pay for the tendered 2028 notes. The filing concerns debt refinancing and does not report earnings or guidance.
Accepts up to $300,000,000 aggregate principal; $697,563,000 principal tendered; proration factor 43.047752%.
Tender Offer Consideration of $981.71 per $1,000 principal, set at a fixed spread of +50 basis points over the 4.250% U.S. Treasury due February 15, 2028 (reference yield 4.773%).
Tender expired 5:00 p.m. New York City time on September 30, 2026; settlement expected October 2, 2026.
Concurrent senior secured notes offering expected to close October 1, 2026, to fund the redemption of the 6.900% Senior Secured Notes due 2027.
Sagimet Biosciences agreed on September 30, 2026 to sell 8,750,010 shares of Series A common stock at $10.00 per share and pre-funded warrants for up to 2,750,010 shares, with net proceeds expected to be $107.5 million. The company plans to use the proceeds with its existing cash to fund a Phase 3 trial of denifanstat in acne, pre-launch activities, and other clinical and corporate needs, and the offering is expected to close on October 1, 2026.
8,750,010 common shares offered at $10.00 per share, plus pre-funded warrants for up to 2,750,010 shares
Expected net proceeds of $107.5 million after underwriting discounts and commissions
Offering expected to close October 1, 2026, subject to customary closing conditions
Underwriters include Leerink Partners LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC as representatives
Streamex Corp. said interim executive chairman Morgan Lekstrom resigned from that role effective September 30, 2026, and will remain an independent board member. The company has not yet named a successor as executive chairperson, so shareholders will not know who will lead the board in that role until one is identified. The filing contains no financial results, despite the Item 2.02 heading.
Lekstrom resigned as interim executive chairman on September 24, 2026, effective September 30, 2026.
He will keep his position as an independent member of the Board of Directors.
No successor as executive chairperson has been identified yet.
The filing includes no revenue, profit, or guidance figures.
On September 30, 2026, Solana Company agreed to sell 4,369,356 Class A shares at $3.433 each to a single institutional investor, with warrants for the same number of shares at $3.776. Gross proceeds are expected to be about $15 million, or about $14.3 million net, and the offering is expected to close on or about October 1, 2026. The issuance adds new shares that existing shareholders will share in, and the company plans to use the proceeds to accumulate SOL, buy back stock, and for working capital and other purposes.
4,369,356 Class A shares sold at $3.433 per share, with warrants for up to 4,369,356 shares at $3.776 per share
Gross proceeds about $15 million; net proceeds about $14.3 million; placement agent cash fee of 4.0% of gross proceeds
Shares priced at a 5% premium to net asset value per share; company reported total NAV of $278 million as of September 24, 2026, with SOL at $119
Closing expected on or about October 1, 2026; Clear Street served as exclusive placement agent
Cheetah Net Supply Chain Service Inc. disclosed progress on its at-the-market share sale program with Pacific Century Securities, which allows sales of Class A common stock of up to $35.3 million. As of September 25, 2026, the company had sold about 196,850,000 shares under the program, before the reverse split took effect on September 28, 2026. After the 1-for-150 reverse split, the company reports about 1,332,087 Class A and 1,358 Class B shares outstanding, a much smaller share count for existing holders.
ATM Offering authorizes sales of Class A common stock with an aggregate offering price of up to $35.3 million, under an agreement entered August 21, 2026
About 196,850,000 shares sold under the ATM Offering as of September 25, 2026, before giving effect to the reverse split
1-for-150 reverse split of Class A and Class B common stock became market effective September 28, 2026
After the split, about 1,332,087 Class A and 1,358 Class B shares are issued and outstanding
On September 24, 2026, a Zone Frontier subsidiary entered a Ground Lease covering about 4,077 acres in Potter County, Texas, for the West Texas data center campus it is developing with HST Technologies. Base rent starts only when construction begins on each site area, and the company can terminate the lease before its inspection period ends, with a refund of its $250,000 deposit subject to a partial non-refundable portion. The lease's commencement depends on conditions such as utility commitments for at least 200 MW of firm service, so the project's path to revenue remains uncertain.
Ground Lease dated September 24, 2026 covers about 4,077 acres; 200 to 800 acres may be designated for data center use and at least 1,800 acres for solar and battery storage
Initial term of 30 years with two 10-year extension options
Base rent is $6,000 per acre per year for the data center area and $1,000 per acre per year for the solar area, beginning only when construction starts on each area
Purchase option for the data center site at $100,000 per acre before on-site power commercial operation, or $135,000 per acre on or after that date; $250,000 deposit is credited against the price if exercised
Newbury Street II disclosed a $350,000 advisory engagement with Donerail Group, an affiliate of former director William Zachre Wyatt, who resigned from the board on September 29, 2026 to avoid a conflict of interest. The company also said it and Fort Robotics confidentially submitted a draft Form S-4 for the proposed business combination, which is expected to close in the fourth quarter of 2026 or the first quarter of 2027, subject to approvals and a shareholder vote.
Donerail engagement letter dated September 29, 2026: $350,000 cash fee plus expense reimbursement up to $75,000, payable at closing.
Sponsor to grant Donerail interests corresponding to about 599,166 Class B ordinary shares upon closing, with an equal amount forfeited by Thomas Bushey.
William Zachre Wyatt resigned as a director effective September 29, 2026; Anthony James Vinciquerra is entitled to 50% of Donerail's net economic interests.
Draft Form S-4 submitted September 29, 2026; the transaction values Fort Robotics at an enterprise value of about $556.6 million and is expected to provide about $201 million in gross proceeds.
Five Point Holdings extended its Development Management Agreement with Heritage Fields El Toro, LLC, owner of the Great Park Neighborhoods community, through December 31, 2028, after the prior term was set to end December 31, 2026. The base fee is unchanged at $13.5 million a year, while incentive compensation drops to 6.75% of future distributions if the agreement is not extended beyond 2028.
Amendment dated September 25, 2026 extends the DMA term to December 31, 2028 (Third Renewal Term)
Annual base fee remains $13.5 million, paid monthly, unchanged from current level
Incentive Compensation is 9% of Great Park Venture distributions; falls to 6.75% for distributions after a non-extension beyond December 31, 2028
Levi Strauss & Co. named John Vandemore, former CFO of Skechers U.S.A., as Executive Vice President and Chief Financial Officer, effective November 1, 2026. He succeeds the role currently held by Harmit Singh, who announced his retirement in April 2026 and will serve as a Special Advisor through November 30, 2026, to support the transition.
Vandemore, 53, was CFO of Skechers U.S.A., Inc. starting November 2017 and previously held finance roles at Mattel and other firms
Base salary of $1,350,000 with an initial target bonus of 110% of base salary
Sign-on award includes a $4,000,000 cash incentive, plus RSU and SAR grants valued at $5,500,000 each
Immix Biopharma agreed on September 29, 2026 to sell 11,363,637 shares of common stock at $11.00 per share in an underwritten offering led by J.P. Morgan Securities LLC. The company expects gross proceeds of $125 million and net proceeds of approximately $117.1 million, with closing expected on September 30, 2026. The company plans to use the proceeds for NXC-201 development, working capital and general corporate purposes.
11,363,637 shares priced at $11.00 per share under an underwriting agreement with J.P. Morgan Securities LLC dated September 29, 2026
Expected gross proceeds of $125 million and net proceeds of approximately $117.1 million after underwriting discounts, commissions and offering expenses
Offering expected to close on or about September 30, 2026, subject to customary conditions; proceeds to fund NXC-201 development, working capital and general corporate purposes
Grindr agreed on September 30, 2026 to acquire PurposeMed Inc., the parent company of the Freddie telehealth PrEP brand, for a base price of $250 million, consisting of $190 million in cash and $60 million in Grindr common stock. The deal also includes an earnout of up to $70 million in cash tied to PurposeMed's fiscal 2027 financial targets. Grindr said the acquisition is expected to have an immaterial impact on its 2026 financial results, and the deal is expected to close in Q4 2026, subject to closing conditions.
Base price of $250 million: $190 million in cash and $60 million in stock, or 3,851,684 shares valued at $15.58 per share
Earnout of up to $70 million in cash, tied to 2027 performance targets and payable in 2028
Freddie expects 2026 revenue of more than $80 million and Adjusted EBITDA of more than $10 million
Expected close in Q4 2026; either party may terminate if closing has not occurred by December 30, 2026
TScan Therapeutics said its Chief Financial Officer, Jason A. Amello, and Chief Medical Officer, Chrystal Louis, will leave the company as part of a strategic reorganization. Both executives signed separation agreements, with employment ending on the earlier of November 1, 2026 or the date they start other paid work, and their pay and benefits continue until then.
Jason A. Amello (CFO) and Chrystal Louis, M.D., MPH (CMO) are departing under separation agreements dated September 24 and September 25, 2026.
Employment ends on the earlier of November 1, 2026 or the executive's start of other employment, consulting or paid board service.
Amello may receive a $85,000 lump-sum cash award and Louis a $125,000 award, each payable if a company milestone is achieved before their separation date under the November 2025 retention program.
Exascale Labs (XLAB) appointed Jake Carney as Chief Financial Officer effective September 25, 2026, ending the interim tenure of Gildas Bonnier, whose service was no longer required after the company's formal search. The filing states Bonnier's departure was not due to any disagreement with the company over operations, policies or practices.
Jake Carney, 38, appointed CFO effective September 25, 2026
Gildas Bonnier ceased serving as Interim CFO effective September 25, 2026
Carney's base salary is $6,000 per month under his employment agreement
Filing states no disagreement led to Bonnier's departure
Jones Lang LaSalle disclosed that Mihir Shah, CEO of Jones Lang LaSalle Technologies and a member of the Global Executive Board, will depart effective April 1, 2027. His separation agreement provides cash severance, a pro-rated incentive payment and other benefits, with equity awards treated under existing plans.
Mihir Shah leaves the company effective April 1, 2027; the separation agreement is dated September 28, 2026
Severance equals 54 weeks of base salary, or $675,000, plus a pro-rated Annual Incentive Plan payment of $590,000 and an additional payment of $2,360,000
Unvested equity awards are forfeited as of the Separation Date, with pro-rated vesting of outstanding awards based on service
Payments are conditioned on a general release of claims; the agreement includes a twelve-month non-solicitation covenant
MSG Knickerbockers entered into agreements on September 30, 2026 to separate its New York Rangers hockey business into MSG Rangers Corp., which will be distributed to its stockholders. The company keeps sole discretion over whether to proceed, and the distribution is expected on October 26, 2026, after which shareholders will hold shares in both companies.
Record date is October 20, 2026; distribution is expected October 26, 2026.
Holders receive one MSG Rangers share for every two shares of MSG Sports common stock held at the record date.
Regular way trading of MSG Knicks (MSGK) and MSG Rangers (MSGR) is expected to begin October 27, 2026.
Completion depends on effectiveness of the Form 10, certain conditions, final league approval and a tax opinion.
Health In Tech said full-year 2026 revenue is expected to be about $33 million, roughly in line with 2025 revenue, and attributed the outlook mainly to the timing of several strategic initiatives. The company also launched HitRix, an AI-powered platform for large-group self-funded health insurance submissions, and said it expects HitRix and related initiatives to contribute more meaningfully beginning in 2027.
2026 revenue outlook of approximately $33 million, roughly in line with 2025 revenue
Outlook reflects timing of HitRix commercialization, the Three-Year Rate Stabilization Program and additional carrier capacity
HitRix platform launched September 30, 2026, for large-group self-funded health insurance workflows
Distribution ecosystem included 933 partners as of June 30, 2026, up 19.9% year over year
Take-Two Interactive entered a new long-term XBOX Publisher License Agreement with Microsoft, dated September 28, 2026 and effective September 17, 2026, that replaces all of its existing Xbox publisher license agreements with Microsoft. The filing describes the company's right to develop, publish, and sell Xbox-compatible products for all Xbox devices, but it does not disclose financial terms such as payment amounts or revenue share percentages.
Agreement signed September 28, 2026, with an effective date of September 17, 2026
Supersedes and replaces all of Take-Two's existing Xbox publisher license agreements with Microsoft
Microsoft has approval rights over each game concept and final version, including packaging and marketing featuring Microsoft's marks
Either party may terminate for material breach or insolvency; full text to be filed with the 10-Q for the period ending September 30, 2026
Albertsons Companies appointed three new directors, William Boltz, Chris Drumgoole and Margaret Ham, effective October 14, 2026, expanding the board from 11 to 14 members. The company also named Senior Vice President Cody Perdue as Interim Chief Financial Officer effective September 30, 2026, after Sharon McCollam's previously announced retirement, so shareholders are seeing a change in the finance leadership while a permanent CFO is sought.
Three directors appointed effective October 14, 2026: William P. Boltz, Chris Drumgoole and Margaret M. Ham; board expands from 11 to 14 directors
Cody Perdue, SVP of Treasury, Investor Relations and Risk Management, named Interim CFO effective September 30, 2026
Perdue receives a stipend at an annual rate of $350,000 during his interim service, in addition to his normal compensation
Sharon McCollam stays in an advisory role through the end of the fiscal year on February 27, 2027; the search for a permanent CFO is underway
BioMarin entered into a Settlement and License Agreement with Ascendis Pharma on September 24, 2026, replacing an August 2026 binding term sheet. Ascendis receives a non-exclusive license to BioMarin patents covering TransCon CNP (navepegritide, Yuviwel), and BioMarin receives royalties on net sales until May 2030. The filing says the parties will dismiss all pending litigation between them over the patents, and it does not disclose dollar amounts.
Agreement dated September 24, 2026, deemed effective August 28, 2026, and supersedes the term sheet reported on August 31, 2026
Royalty of 20% of annual net sales in the United States and 18% in the EU, Brazil and South Korea, until May 2030
Pending litigation between the parties relating to the BioMarin patent rights to be dismissed with prejudice
Ascendis agreed not to challenge BioMarin's patent rights; no dollar figures disclosed
CTO Realty Growth entered into a $1.0 billion amended and restated unsecured credit agreement with KeyBank as administrative agent, dated September 29, 2026, replacing its prior facility. Proceeds repaid its previous $300 million revolving credit facility and two term loans of $100 million each due in January 2027 and January 2028. The company says the deal extends debt maturities to 2029 through 2032 and adds $250 million of commitments, which lengthens its weighted average debt maturity to 4.3 years from 1.6 years, excluding extension options.
Facilities total $1.0 billion: a $400 million revolver due September 2030 with two six-month extension options, plus four $150 million term loans due September 2029, September 2030, September 2031 and March 2032
Total commitments increase by $250 million, with an accordion feature allowing up to $1.5 billion in aggregate commitments
Initial fixed rates after SOFR swaps are 5.3% (2029 loan), 4.9% (2030 loan), 4.8% (2031 loan) and 3.4% (2032 loan), with the 2032 rate adjusting to about 5.3% in February 2027
Company is subject to customary restrictive covenants and financial maintenance covenants
MoonLake Immunotherapeutics said it submitted a Biologics License Application to the U.S. Food and Drug Administration on September 30, 2026, seeking approval of its tri-specific nanobody sonelokimab for moderate-to-severe hidradenitis suppurativa in adults and patients 12 years and older. The filing marks a regulatory step toward a possible approval, but the FDA has not yet decided whether to accept the application for review.
BLA submitted to the FDA on September 30, 2026 for sonelokimab in moderate-to-severe hidradenitis suppurativa
FDA acceptance decision expected within approximately 60 days of submission
Planned review timeline expected from the FDA within approximately 74 days of submission
Ultra Clean Holdings appointed Alexander Davern to its Board of Directors, effective September 28, 2026. The filing says he has more than 30 years of industrial technology experience, including service as CEO of National Instruments from 2017 to 2020, and the appointment does not include any financial results or guidance.
Appointed to the Board effective September 28, 2026; announced in a press release dated September 30, 2026
Previously served at National Instruments from 1994 to 2020, including as CEO from 2017 to 2020 and CFO from 1998 to 2010
Currently an independent director of Cirrus Logic, Computer Modelling Group and Spectris plc
Will receive director compensation under the non-employee director policy and is expected to sign the standard indemnification agreement
Regeneron's Compensation Committee granted CEO Leonard Schleifer and CSO George Yancopoulos one-time performance share units effective September 24, 2026, replacing their annual equity awards through 2036. Payouts depend on new product filings, approvals and revenue from new products over a performance period ending December 31, 2035, with a maximum of 2,700,000 PSUs for the CEO and 2,900,000 for the CSO. The filing also discloses that both executives received equity stakes in a newly formed, majority-owned subsidiary that the company says has nominal value and no significant assets.
Grant effective September 24, 2026; performance period runs January 1, 2026 through December 31, 2035
Revenue-based earnout starts at $10 billion of new product annual revenues and the maximum requires about $30 billion
Award caps are 2,700,000 PSUs for the CEO and 2,900,000 PSUs for the CSO; shares are subject to a holding period until February 2036
Both executives received stakes in a new subsidiary formed to explore a non-core business that has not yet commenced operations
Burke & Herbert Financial Services Corp. completed a $100 million public offering of 7.00% fixed-to-floating rate subordinated notes due October 1, 2036, with the offering priced at 100% of principal. The company plans to use the proceeds, plus cash on hand, to repay several existing subordinated notes and potentially redeem part of its 2021 Preferred Stock, and to provide capital to its bank subsidiary.
$100.0 million of 7.00% fixed-to-floating rate subordinated notes due October 1, 2036, sold at 100% of principal through Keefe, Bruyette & Woods, Inc.
Fixed 7.00% interest until October 1, 2031, then floating at Three-Month Term SOFR plus 222 basis points
Proceeds plus cash on hand earmarked to repay $4.5 million 2028 note, $18.1 million July 2030 notes and $20.0 million October 2030 notes, and potentially repay $75.0 million of 3.25% notes due 2031
Offering expected to close September 30, 2026; notes intended to qualify as Tier 2 capital
On September 30, 2026, Vroom Automotive, LLC, a Vroom subsidiary, issued 16,000 Series A1 and 4,000 Series B1 preferred units to SPE Holdings 2026-1 for $20 million in gross proceeds. The units carry quarterly preferential distributions tied to SOFR plus 8.50% or 9.25%, and the Series B1 units are convertible into common units of Vroom Automotive at SPE Holdings' option. Vroom Automotive expects to use the proceeds to repay certain obligations and to purchase residual interests in certain asset-backed securitization trusts.
Gross proceeds of $20,000,000 from 16,000 Series A1 and 4,000 Series B1 preferred units
Distribution rate resets quarterly at 90-day average SOFR plus 8.50% (Series A1) or 9.25% (Series B1)
Series B1 units are convertible into common units at SPE Holdings' option; Series A1 units are not convertible
Agreement and A&R LLC Agreement dated September 30, 2026, filed as exhibits 10.1 and 10.2
Arhaus, Inc. announced that K.C. Moss has been appointed as its first Chief Digital Officer, effective September 30, 2026, a newly created executive role. Moss will lead digital strategy, including eCommerce, digital product and experience, personalization, and client data and analytics, and will report directly to Founder and CEO John Reed.
K.C. Moss appointed first Chief Digital Officer, effective September 30, 2026
Moss reports directly to John Reed, Founder and Chief Executive Officer, and joins the executive leadership team
Role covers eCommerce, digital product and experience, personalization, and client data and analytics
Moss has more than 25 years of experience building and leading digital businesses
Rank One Computing Corp (ROC) entered into an eight-year Contract for Commercial Products and Commercial Services with the U.S. Department of Justice's Executive Office for United States Attorneys to develop and support a Digital Evidence Review Platform. The filing says the aggregate potential payment is $64.3 million if all seven option periods are exercised, but only the one-year base period is funded, and the option periods are at the government's discretion and subject to appropriations.
Contract dated September 14, 2026; base period runs September 22, 2026 through September 21, 2027, with payment of $7,414,143.80 for that period.
Aggregate potential payment of $64,301,418.24 over the eight-year term if EOUSA exercises all seven option periods.
Option periods are exercisable at the government's discretion and subject to the availability of appropriations.
Company announced the award in a press release dated September 28, 2026, filed as Exhibit 99.1.
Diamondback Energy amended its Stockholders Agreement with SGF FANG Holdings, LP, tying the Stephens group's board designation rights to its ownership level. Directors Darin Holderness and Lance Robertson resigned from the board in connection with a Board Stepdown under that agreement, not because of any disagreement with the company.
Amendment dated September 29, 2026 lets the Stephens Majority designate two directors if Stephens Stockholders own at least 10% but less than 25% of outstanding shares.
The Stephens Stockholders would have no designated directors if they own less than 10% of outstanding shares.
Darin Holderness resigned from the board on September 29, 2026; Lance Robertson resigned on September 30, 2026.
Resignations were stated to be unrelated to any disagreement with the company on operations, policies or practices.
Cars.com said CFO Sonia Jain will leave the role effective November 6, 2026, and stay on as an Executive Advisor until March 31, 2027. Trent Ziegler, former CFO of FairSquare, will become CFO on November 6, 2026, after joining as CFO-Designate on October 19, 2026. The change is a senior finance leadership transition, and the filing discloses no financial results or guidance changes.
Sonia Jain ceases to be CFO effective November 6, 2026; she receives $250,000 during her advisory period through March 31, 2027
Trent Ziegler, age 43, previously CFO of FairSquare, Inc. (August 2024 to September 2026) and earlier CFO of LendingTree, Inc.
Ziegler compensation: $475,000 base salary, 80% bonus target, $3,500,000 target-value RSU grant, and a $275,000 signing bonus
Sonoco Products entered into a first amendment to its credit agreement on September 25, 2026, adding two term loan facilities totaling $800 million. It borrowed $500 million on the closing date and used it to refinance an existing $500 million term loan that was due in August 2028, with the remaining $300 million available for future refinancings.
New $400 million Tranche A term loan matures December 31, 2029, with no scheduled payments before maturity
New $400 million Tranche B delayed-draw term loan matures December 31, 2031; $100 million drawn at closing and $300 million remaining
$500 million borrowed on September 25, 2026 refinances an existing $500 million syndicated term loan scheduled to mature in August 2028
Interest margins are tied to senior unsecured debt ratings from S&P and/or Moody's
TD SYNNEX amended its trade receivables securitization program on September 25, 2026, extending the maturity to September 25, 2028 and raising lender commitments to $3.0 billion. The filing also lowers the program fee rates on used commitments to 0.725% (commercial paper funded) and 0.825% (other funding), and the lenders received an upfront fee.
Maturity extended to September 25, 2028
Aggregate lender commitment increased to $3,000,000,000
Program fee on used portion set at 0.725% per annum for commercial paper funding and 0.825% for other funding
Lenders were paid an upfront fee; the filing does not state its amount
Lee Enterprises appointed Gregory Hoffmann, age 37, as a director effective immediately, with a term running until its 2028 annual meeting, and placed him on the Nominating and Corporate Governance Committee. The filing discloses that he is the son of Chairman and majority stockholder David Hoffmann, and it lists related-party dealings between the company and the Hoffmann family, including a management agreement with Hoffmann Media Group. The filing reports no financial results, so the change is governance-related rather than a measure of operating performance.
Board appointment made September 24, 2026; announced in a press release dated September 30, 2026
Gregory Hoffmann serves as Co-Chief Executive Officer of Hoffmann Family of Companies and has been CEO of Hoffmann Commercial Real Estate since April 2017
He is the son of David Hoffmann, Chairman and majority stockholder, who bought 10,909,440 shares in a February 5, 2026 private placement
Hoffmann Media Group pays a fixed management fee of $135,000 per fiscal quarter under a May 14, 2026 five-year agreement
Digimarc agreed on September 29, 2026 to sell 4,500,000 common shares at $4.04 per share in a registered direct offering, with gross proceeds expected to be about $18.2 million and closing expected on or about September 30, 2026. The company plans to use the net proceeds for general corporate purposes, and the filing adds investor participation rights in future equity offerings and a limit on most new share issuance through December 31, 2026, which shareholders should weigh alongside the new share count.
4,500,000 common shares offered at $4.04 per share; gross proceeds expected to be about $18.2 million
Closing expected on or about September 30, 2026, subject to customary closing conditions
Needham & Company acted as sole placement agent; shares sold under an S-3 registration statement declared effective July 13, 2026
Investors get participation rights in future equity offerings until the earlier of the third anniversary of closing or when the two most recent quarters show positive EBIT and operating cash flow
Rent the Runway launched a $15 million rights offering on September 30, 2026, giving eligible Class A stockholders the right to buy additional shares. Holders who keep their shares can use the rights to buy shares at $3.55 each, and the rights expire on October 14, 2026 unless extended.
Rights offering size: $15 million, launched September 30, 2026
Record date: 5:00 p.m. New York City time on September 25, 2026; each share held received one right
Each right entitles the holder to buy approximately 0.1251 Class A shares at $3.55 per share; no fractional shares will be issued
Rights expire at 5:00 p.m. New York City time on October 14, 2026, unless extended
Carlsmed said CFO Leo Greenstein left the role effective September 25, 2026, and appointed Richard Heppenstall as CFO effective September 28, 2026. Greenstein's separation includes $500,000 in cash severance, accelerated vesting of some equity awards, and a $60,000 advisory fee through December 31, 2026. The company reaffirmed its full-year 2026 revenue guidance of $74 million to $78 million, so the leadership change did not come with a change to that outlook.
Greenstein's departure effective September 25, 2026; Heppenstall's appointment effective September 28, 2026.
Greenstein to receive $500,000 in cash payments, equal to 12 months of base salary, plus a $60,000 advisory fee.
Heppenstall's employment agreement sets a $500,000 base salary and a target bonus of 60% of base, with $1.4 million each in inducement stock options and RSUs.
Full-year 2026 revenue guidance of $74 million to $78 million was reaffirmed.
Trio Petroleum's Canadian subsidiary agreed on September 25, 2026 to buy Marlin Resources' interests in 24 oil wells, including four producing wells and 20 shut-in heavy-oil assets, for CAD$800,000 in cash plus the transfer of certain assets and a water disposal arrangement. The company announced the signing on September 30, 2026, and the filing says the agreement is subject to customary closing conditions. The deal matters to shareholders because it would add current production of about 37 barrels of oil per day and a proposed multilateral drilling well, though the filing does not give a closing date or financial results.
Agreement dated September 25, 2026, between Trio Petroleum Canada, Corp. and Marlin Resources Ltd.; cash consideration CAD$800,000 plus conveyance of certain Trio assets and interests to Marlin
Acquired assets: 24 oil wells, including four producing wells and 20 shut-in heavy-oil assets, in Saskatchewan's Lloydminster region
Press release cites about 37 barrels of oil per day of current production and a Cummings multilateral well budget of CDN$1.2 million, plus a CDN$425,000 workover program
Purchase price and anticipated development and workover costs to be funded from Trio's cash on hand
Indaptus Therapeutics agreed on September 29, 2026 to extend the outside date for the closing of its $24.0 million private placement of common stock from September 29 to October 16, 2026. The notices and consents also let the company defer closing until purchaser closing conditions are met or waived, and extend the purchasers' funding deadline and related termination rights to the same date. For shareholders, the filing shows the financing has not yet closed and its timing now depends on the extended deadline.
Private placement of common stock with aggregate gross proceeds of approximately $24.0 million, before offering expenses, agreed on September 8, 2026
Outside date extended from September 29, 2026 to October 16, 2026 for each purchaser
Company may defer closing until purchaser closing conditions are satisfied or waived, but no later than October 16, 2026, unless otherwise agreed in writing
All other terms of the Purchase Agreement remain unchanged
Silexion Therapeutics said it has dosed the first patient worldwide in its Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, at Tel Aviv Sourasky Medical Center in Israel. The filing says additional sites in Israel and Germany are expected to join in the coming months, and the company refers to preliminary clinical readouts in the near term. The filing reports no financial results, guidance, or financing terms.
First patient dosed at Tel Aviv Sourasky Medical Center (Ichilov); announced September 30, 2026
Trial plans an initial safety run-in cohort of approximately 18 patients, then a randomized cohort of approximately 166 patients
SIL204 is given with standard chemotherapy versus chemotherapy alone in patients with unresectable Stage 3 locally advanced pancreatic cancer with a confirmed KRAS mutation
Additional Israeli and German sites are expected to join in the coming months
Mattel's CEO Ynon Kreiz resigned as CEO and chairman effective October 2, 2026, and the board named director Roger Lynch as chairman effective that date and as CEO no later than November 2, 2026. Jonathan Anschell will serve as interim principal executive officer until Lynch takes over, and the filing discloses Lynch's pay package, including a $2,300,000 base salary and $10,600,000 make-whole signing bonus.
Ynon Kreiz resigned as CEO and chairman effective October 2, 2026, to take a senior role at another public company
Roger Lynch, a board member since 2018, becomes chairman October 2, 2026 and CEO no later than November 2, 2026
Lynch's offer letter includes a $2,300,000 base salary, a 200% target bonus, and a $10,600,000 make-whole signing bonus
Diana Ferguson was named Independent Lead Director effective October 2, 2026
Trump Media & Technology Group (TMTG) and TAE Technologies signed an amended and restated convertible promissory note that replaces a December 18, 2025 note tied to their pending all-stock merger. The amended note carries an initial $200 million first tranche, allows up to an additional $100 million second tranche, and caps total principal at $300 million plus PIK interest, so TMTG's financial exposure to TAE rises if the second tranche is drawn. The companies also filed a Form S-4 registration statement for the merger, which has not yet become effective.
First tranche principal is $200 million; TAE may request up to $100 million more during a second tranche draw period.
Second tranche draw period ends on the earlier of November 29, 2026 or termination of the merger agreement; each drawdown must be at least $50 million.
Interest accrues at 7% per year and is paid in kind by adding to principal; accrued interest under the note was $10,969,863.01 as of signing.
The note converts automatically on a qualified TAE financing of at least $300 million, and TMTG gets pre-conversion voting rights tied to 25% of the outstanding amount.
Celcuity announced on September 30, 2026 that REVTORPYK (gedatolisib) is now commercially available in the United States, following FDA approval on July 14, 2026 for certain HR+/HER2- advanced breast cancer patients without a PIK3CA mutation. The filing marks the start of commercial sales for the company's first FDA-approved product, though it does not disclose any sales, revenue or financial figures.
FDA approved REVTORPYK on July 14, 2026, in combination with palbociclib and fulvestrant, and with fulvestrant alone.
Eligible patients are those with HR+/HER2- advanced breast cancer without a PIK3CA mutation who progressed after at least one line of endocrine therapy in the metastatic setting.
Celcuity launched the REVTORPYK Support Services program to help with insurance coverage and financial assistance.
A supplemental New Drug Application for the PIK3CA mutated population was submitted to the FDA in August 2026.
AEON Biopharma received official minutes from its FDA Type 2b meeting on the development path for ABP-450, a proposed biosimilar to BOTOX. The FDA agreed in principle with the company's two-stage pharmacodynamic study design and said previously completed Daewoong comparative studies may be submitted as supportive evidence, while the company will not start a standalone comparative efficacy study for now. The filing also says the Two-Year Milestone Warrants will expire on November 16, 2026, which affects warrant holders.
FDA agreed in principle with the two-stage CMAP pharmacodynamic study design; company expects to file an IND in Q4 2026 and start the study in Q1 2027
Previously completed Daewoong comparative studies may be considered as supportive evidence, subject to scientific bridging
No standalone comparative efficacy study planned at this time; company plans to return to the FDA in 2027
Two-Year Milestone Warrants will expire on November 16, 2026, unless exercised before that date
General Mills' board elected Chief Operating Officer Dana McNabb as chief executive, succeeding Jeffrey Harmening, who is retiring as CEO and will serve as Executive Chair of the board. Both appointments take effect January 1, 2027, and the board also set new pay levels for each executive.
McNabb's CEO base salary will be $1,350,000, with an annual cash incentive target of 180% of base salary, plus an incremental long-term incentive award of $2,100,000.
Harmening's base salary as Executive Chair will be reduced to $1,100,000, and his annual cash incentive target will decrease to 125% of base salary.
McNabb has been Chief Operating Officer since June 2026 and joined General Mills in 1999.
Atlantic HPC Group, the target in Aperture AC's planned business combination, completed its acquisition of Valley Oasis Development LLC on September 23, 2026, adding two power contracts for 29 MW of aggregate contract demand and a one-acre land lease in Dyersburg, Tennessee. The filing says the acquisition raises Atlantic's total utility-approved capacity to 127 MW, of which 76 MW is under development, and the filing does not disclose the purchase price or the effect on financial results.
Acquisition of 100% of Valley Oasis membership interests completed September 23, 2026
Two power contracts with Dyersburg Electric System, each dated September 3, 2026, for 14.5 MW of contract demand
About 14.5 MW can be served on existing infrastructure after utility construction; the remaining 14.5 MW requires transformer upgrades
Land lease covers about one acre and expires in March 2036 without an option to extend
Winchester Bancorp's board adopted a share repurchase program allowing the company to buy back up to 464,769 shares of common stock, or about 5% of its current outstanding shares. The program runs from September 30, 2026 to September 1, 2027, and buybacks will depend on price, regulatory requirements, and market conditions. For shareholders, a buyback of this size can reduce the number of shares outstanding, but the filing gives no commitment that the full amount will be repurchased.
Authorization covers up to 464,769 shares, about 5% of current outstanding common stock
Program commences September 30, 2026 and expires September 1, 2027
Timing and amount depend on price, regulatory considerations, market conditions, and liquidity priorities
Program may be modified, suspended, or discontinued at any time
Moderna appointed Juan Andres, a former Moderna executive who retired in 2023, as its new Chief Operating Officer, effective October 5, 2026, reporting to CEO Stephane Bancel. The company also said Chief Technical Operations and Quality Officer Jerh Collins will retire, so the appointment adds a senior operations role while a manufacturing leader departs.
Juan Andres, 62, starts as COO on October 5, 2026 and will serve on the Executive Committee.
Andres receives an initial base salary of $800,000 and a target annual bonus of 90% of base salary.
A new hire equity award with total value of $5,000,000 is subject to four-year vesting; annual equity target is $4,000,000 to $5,000,000.
Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, will retire; the filing gives no retirement date.
Jade Biosciences announced preclinical data for JADE301, its anti-interferon beta antibody being developed for dermatomyositis, a rare autoimmune disease. The company said the data show high-affinity IFN-ß neutralization, a longer half-life than a dazukibart comparator, and good nonclinical tolerability, and it expects to start a Phase 1 trial in the fourth quarter of 2026.
JADE301 binds IFN-ß with a K D of 11.3 pM, about 2.5-fold higher affinity than the dazukibart comparator.
Non-human primate half-life is about 30 days after IV dosing, roughly 3-fold longer than the comparator.
Planned placebo-controlled Phase 1 trial in 24 healthy volunteers to start in Q4 2026, with interim data expected in the second half of 2027.
On September 29, 2026, Capital Bancorp agreed to merge into Peoples Bancorp in an all-stock deal, with each Capital share converting into 1.11 Peoples shares. The companies put the aggregate transaction value at about $728.1 million, or $43.75 per Capital share, and expect the deal to close in the first half of 2027, subject to regulatory and shareholder approvals. Capital shareholders would hold about 32% of the combined company.
Each Capital share converts into 1.11 Peoples shares; aggregate value about $728.1 million, or $43.75 per share, based on Peoples' 20-day volume-weighted average price of $39.41 as of September 29, 2026.
Capital must pay Peoples a termination fee of $30.66 million in certain specified circumstances.
Former Capital shareholders are expected to own about 32% of Peoples; three Capital directors are expected to join the Peoples board.
Closing is expected in the first half of 2027; Capital directors and executive officers signed support agreements to vote in favor of the merger.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.